Insurers scrutinize drug costs after $84,000 Sovaldi surprise

May 28, 2014 8:30 AM

42 0

Insurers scrutinize drug costs after $84,000 Sovaldi surprise

NEW YORK/LOS ANGELES: Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, US health insurers are trying to make sure they aren't blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.

Manufacturer Gilead Sciences Inc says 30,000 people have received hepatitis drug Sovaldi so far, and that sales hit a record-breaking $2.3 billion within a few months. The treatment, typically 84 pills taken over 12 weeks, completely cures the disease in more than 90 percent of patients.

Also read: House Passes Health Bill to Speed Drug Approvals, Boost Biomedical Research

Read more

To category page

Loading...